Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Kinnate, a Precision Oncology Company, Pays $24 Million to Buy Out JV Partners

publication date: Feb 22, 2023

San Francisco’s Kinnate Biopharma bought out Series A investors in Kinnjiu, a Kinnate joint venture formed to bring kinase inhibitors to Greater China. The company paid $24 million to acquire all issued and outstanding Series A preferred Kinnjiu shares from OrbiMed and Foresite Capital Management, using a combination of Kinnate shares and cash. Kinnate, a clinical-stage precision oncology company, said the acquisition will not hurt its cash runway. The company also announced that it has started a China Phase I clinical trial of its pan-RAF inhibitor, exarafenib. More details....

Stock Symbol: (NSDQ: KNTE)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital